MARKET INTRODUCTION
Biosimilars are similar to reference drugs. However, they exhibit a minor difference in clinically inactive components. They are identical in terms of safety, effectiveness, and clinical significance as their reference product. Biologics are produced from living organisms by using complex manufacturing processes. A wide variety of biologics are available such as monoclonal antibodies, therapeutic proteins, vaccines, and others. These are active substances obtained from living cells of plants or animals. Biosimilars are approximately 20-25% cheaper than their reference/branded products. Moreover, biologics are used in the treatment of a wide variety of indications such as osteoporosis, arthritis, cystic fibrosis, autoimmune disorders, and cancer. For instance, some of the approved biosimilars are Mvasi (Avastin), Erelzi (Enbrel), Ogivri (Herceptin), Amjevita (Amjevita), among others.
MARKET DYNAMICS
In the last two decades, the biotechnology industry developed a wide range of biologic drugs, changing the medicine landscape worldwide. Biologics are being successfully being used to treat many chronic diseases. The increasing availability of biosimilars is contributing to the growth of the market. For instance, Biogen, which is a prominent manufacturer of biosimilar therapies, offers an anti-TNF therapies portfolio. These are used for the treatment of various inflammatory conditions like rheumatoid arthritis, bowel disease, psoriatic arthritis, among others. Biosimilars are helping in expanding cost-effective treatment options for chronic diseases. Increasing cases of life-threatening diseases are growing demand for such therapies. Additionally, emerging markets such as China, India, are broadening the scope of the market and presenting growth opportunities for future growth.
MARKET SCOPE
The "Global Biologics and Biosimilars Market Analysis to 2031" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of biologics and biosimilars market with detailed market segmentation by product, application and geography. The global biologics and biosimilars market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading biologics and biosimilars market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global biologics and biosimilars market is segmented on the basis of product and application. Based on product, the market is segmented as recombinant glycosylated proteins, recombinant non-glycosylated proteins and recombinant peptides. Recombinant glycosylated proteins are further sub segmented into monoclonal antibodies, erythroprotein, and others. Recombinant non-glycosylated proteins are further sub divided into insulin, Granulocyte Colony-stimulating Factor, and interferon. Based on indication, the market is segmented as chronic diseases, oncology, autoimmune diseases, infectious diseases, blood disorders, growth hormone deficiency and other.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global biologics and biosimilars market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The biologics and biosimilars market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting biologics and biosimilars market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the biologics and biosimilars market in these regions.
Biologics and Biosimilars Market Report Analysis
CAGR (2023 - 2031)
US$ XX Million
US$ XX Million
Report Coverage
Key Players
Regional Overview
Market Segmentation
By Product
By Indication
The report covers key developments in the biologics and biosimilars market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from biologics and biosimilars market are anticipated to lucrative growth opportunities in the future with the rising demand for biologics and biosimilars market in the global market. Below mentioned is the list of few companies engaged in the biologics and biosimilars market.
The report also includes the profiles of key biologics and biosimilars market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Pfizer Inc.
- Intas Pharmaceuticals Ltd.
- Biocon
- Dr. Reddy's Laboratories Ltd.
- Sandoz International GmbH (Novartis division)
- CELLTRION INC.
- Amgen Inc.
- STADA Arzneimittel AG
- Apotex Inc.
- Biogen
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
Biologics and Biosimilars Market Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ XX Million |
| Market Size by 2031 | US$ XX Million |
| Global CAGR (2023 - 2031) | XX% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Product
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Trends and growth analysis reports related to Pharmaceuticals : READ MORE..
The List of Companies
1. Pfizer Inc.
2. Intas Pharmaceuticals Ltd.
3. Biocon
4. Dr. Reddy's Laboratories Ltd.
5. Sandoz International GmbH (Novartis division)
6. CELLTRION INC.
7. Amgen Inc.
8. STADA Arzneimittel AG
9. Apotex Inc.
10. Biogen
Get Free Sample For